Analysis of Halozyme Therapeutics, Inc.'s recent developments including revenue growth, patent expiration concerns, and new ...

Halozyme made the €11-per-share offer earlier this month, valuing Evotec at around €2 billion ($2.1 billion), saying at the ...

SAN DIEGO, Nov. 27, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that members of the executive leadership team are scheduled to present and host ...

The local company announced Friday morning at 5:35 a.m. that it was withdrawing its bid to buy Evotec for about $11.52 per ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that members of its executive leadership team will present and host investor meetings at several upcoming conferences. **Details on the ...

Halozyme has withdrawn its offer to buy biopharmaceutical services firm Evotec for €2 billion, a move that comes after repeated requests to meet with the company to discuss a deal were all ...

On Monday, H.C. Wainwright maintained its Buy rating and $68.00 price target for Halozyme Therapeutics (NASDAQ:HALO). The firm's decision follows Halozyme's recent withdrawal of its proposal to ...

In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Halozyme (HALO – Research Report), with a price ...

On Friday, Halozyme Therapeutics, Inc. (HALO) stock saw a modest uptick, ending the day at $49 which represents a slight increase of $3.30 or 7.22% from the prior close of $45.7. The stock opened at ...